Synthesis and anticancer activity evaluation of a series of [1,2,4] triazolo[1,5-a]pyridinylpyridines in vitro and in vivo

European Journal of Medicinal Chemistry

Volumn 67, Issue , 2013, Pages 243-251

  Wang, Xiao Meng ^a   Xu, Jing ^a   Li, Yi Ping ^a   Li, Huan ^a   Jiang, Cong Shan ^a   Yang, Guang De ^a   Lu, She Min ^a   Zhang, San Qi ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Anticancer effect; Antiproliferative activities; Synthesis; 1,2,4 Triazolo 1,5 a pyridine

Indexed keywords

ANTINEOPLASTIC AGENT; ETHYL 2 [6 [6 METHOXY 5 (4 FLUOROPHENYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YLAMINO]ACETATE; N [5 (2 AMINO[1,2,4]TRIAZOLO[1,5 A]PYRIDIN 6 YL) 2 METHOXYPYRIDIN 3 YL] 4 CHLOROPHENYLSULFONAMIDE; N [5 (2 AMINO[1,2,4]TRIAZOLO[1,5 A]PYRIDIN 6 YL) 2 METHOXYPYRIDIN 3 YL] 4 FLUOROPHENYLSULFONAMIDE; N [5 (2 AMINO[1,2,4]TRIAZOLO[1,5 A]PYRIDIN 6 YL) 2 METHOXYPYRIDIN 3 YL] 4 METHYLPHENYLSULFONAMIDE; N [5 [2 (2 ETHOXYETHYLAMINO)[1,2,4]TRIAZOLO[1,5 A]PYRIDIN 6 YL) 2 METHOXYPYRIDIN 3 YL] 4 FLUOROPHENYLSULFONAMIDE; N [5 [2 (2 METHOXYETHYLAMINO)[1,2,4]TRIAZOLO[1,5 A]PYRIDIN 6 YL) 2 METHOXYPYRIDIN 3 YL] 4 FLUOROPHENYLSULFONAMIDE; N [6 [6 CHLORO 5 (4 FLUOROPHENYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL]ACETAMIDE; N [6 [6 CHLORO 5 (4 FLUOROPHENYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL]CYCLOPROPANECARBOXAMIDE; N [6 [6 CHLORO 5 (4 METHYLPHENYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL]ACETAMIDE; N [6 [6 METHOXY 5 (2,4 DIFLUOROPHENYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL]ACETAMIDE; N [6 [6 METHOXY 5 (4 CHLOROPHENYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL]ACETAMIDE; N [6 [6 METHOXY 5 (4 CYCLOPROPYLCARBONYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL]ACETAMIDE; N [6 [6 METHOXY 5 (4 FLUOROPHENYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL]ACETAMIDE; N [6 [6 METHOXY 5 (4 FLUOROPHENYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL]CYCLOPROPANECARBOXAMIDE; N [6 [6 METHOXY 5 (4 METHOXYPHENYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL]ACETAMIDE; N [7 [6 METHOXY 5 (4 CHLOROPHENYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL]ACETAMIDE; N [7 [6 METHOXY 5 (4 FLUOROPHENYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL]ACETAMIDE; N [7 [6 METHOXY 5 (4 METHYLPHENYLSULFONAMIDO)PYRIDIN 3 YL][1,2,4]TRIAZOLO[1,5 A]PYRIDIN 2 YL]ACETAMIDE; PROTEIN KINASE B; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; [1,2,4]TRIAZOLO[1,5 A]PYRIDINYLPYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DRUG ACETYLATION; DRUG MEGADOSE; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOLECULAR DOCKING; MOUSE; NONHUMAN; SARCOMA 180; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION;

ANTICANCER EFFECT; ANTIPROLIFERATIVE ACTIVITIES; SYNTHESIS; [1,2,4]TRIAZOLO[1,5-A]PYRIDINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HUMANS; MCF-7 CELLS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES; TUMOR CELLS, CULTURED;

EID: 84882562598     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.06.052     Document Type: Article

References (26)

1. B.J. Dugan, D.E. Gingrich, E.F. Mesaros, K.L. Milkiewicz, M.A. Curry, A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779, J. Med. Chem. 55 (2012) 5243-5254.
2. M.M. Seavey, L.D. Lu, K.L. Stump, N.H. Wallace, W. Hockeimer, T.M. O'Kane, B. Ruggeri, P. Dobrzanski, Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer, Mol. Cancer Ther. 11 (2011) 984-993.
3. K.L. Stump, L.D. Lu, P. Dobrzanski, C. Serdikoff, D.E. Gingrich, B.J. Dugan, T.S. Angeles, M.S. Albom, M.A. Ator, B.D. Dorsey, B.A. Ruggeri, M.M. Seavey, A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis, Arthritis Res. Ther. 13 (2011) R68.
4. L.A.T. Cleghorn, A. Woodland, I.T. Collie, L.S. Torrie, N. Norcross, T. Luksch, C. Mpamhanga, R.G. Walker, J.C. Mottram, R. Brenk, A.F. Julie, H.G. Ian, G.W. Paul, Identification of inhibitors of the leishmania cdc2-related protein kinase CRK3, ChemMedChem 6 (2011) 2214-2224.
5. P.T. Hawkins, K.E. Anderson, K. Davidson, L.R. Stephens, Signalling through class I PI3Ks in mammalian cells, Biochem. Soc. Trans. 34 (2006) 647-662. (Pubitemid 44796393)
6. T.D. Cushing, D.P. Metz, D.A.Whittington, L.R.McGee, PI3Kd and PI3Kg as targets for autoimmune and inflammatory diseases, J.Med. Chem. 55 (2012) 8559-8581.
7. K. Bell, M. Sunose, K. Ellard, A. Cansfield, J. Taylor, SAR studies around a series of triazolopyridines as potent and selective PI3Kg inhibitors, Bioorg. Med. Chem. Lett. 22 (2012) 5257-5263.
8. G. Bergamini, K. Bell, S. Shimamura, T. Werner, A. Cansfield, A selective inhibitor reveals PI3Kg dependence of TH17 cell differentiation, Nat. Chem. Biol. 8 (2012) 576-583.
9. K. Ellard, M. Sunose, K. Bell, N. Ramsden, G. Bergamini, G. Neubauer, Discovery of novel PI3Kg/d inhibitors as potential agents for inflammation, Bioorg. Med. Chem. Lett. 22 (2012) 4546-4549.
10. J. Kuroyanagi, K. Kanai, Y. Sugimoto, T. Fujisawa, C. Morita, Novel antifungal agents: triazolopyridines as inhibitors of b -1,6-glucan synthesis, Bioorg. Med. Chem. 18 (2010) 5845-5854.
11. S.P. East, C.B. White, O. Barker, S. Barker, J. Bennett, DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity, Bioorg. Med. Chem. Lett. 19 (2009) 894-899.
12. S.D. Edmondson, A. Mastracchio, R.J. Mathvink, J.F. He, B. Harper, (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N, N-dimethyl-4-oxo-2-(4-[1,2,4] triazolo[ 1,5- a]-pyridin-6-ylphenyl)butanamide: a selective a-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, J. Med. Chem. 49 (2006) 3614-3627. (Pubitemid 43902466)
13. S.K. Grant, Therapeutic protein kinase inhibitors, Cell. Mol. Life Sci. 66 (2009) 1163-1177.
14. J.A. Engelman, J. Luo, L.C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nat. Rev. Genet. 8 (2006) 606-619. (Pubitemid 44100518)
15. L. Salmena, A. Carracedo, P.P. Pandol fi, Tenets of PTEN tumor suppression, Cell 133 (2008) 403-414. (Pubitemid 351622014)
16. P. Liu, H. Cheng, T.M. Roberts, J. Zhao, Targeting the phosphoinositide 3-kinase pathway in cancer, Nat. Rev. Drug Discov. 8 (2009) 627-644.
17. Q. Liu, C. Thoreen, J.H. Wang, D. Sabatini, N.S. Gray, mTOR mediated anticancer drug discovery, Drug Discov. Today Ther. Strategy 6 (2009) 47-55.
18. P. Wu, Y.Z. Hu, Small molecules targeting phosphoinositide 3-kinases, Med. Chem. Commun. 3 (2012) 1337-1355.
19. S.D. Knight, N.D. Adams, J.L. Burgess, Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin, ACS Med. Chem. Lett. 1 (2010) 39-43.
20. N. Nishimura, A. Siegmund, L. Liu, Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structureeactivity relationships of a series of quinoline and quinoxaline derivatives, J. Med. Chem. 54 (2011) 4735-4751.
21. N.D. D'Angelo, T.-S. Kim, K. Andrews, S.K. Booker, Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors, J. Med. Chem. 54 (2011) 1789-1811.
22. M.M. Stec, K.L. Andrews, S.K. Booker, S. Caenepeel, Structureeactivity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stability, J. Med. Chem. 54 (2011) 5174-5184.
23. M.H. Norman, K.L. Andrews, Y.Y. Bo, S.K. Booker, S. Caenepeel, V.J. Cee, Selective class I phosphoinositide 3-kinase Inhibitors: optimization of a series of pyridyltriazines leading to the identi fication of a clinical candidate, AMG 511, J. Med. Chem. 55 (2012) 7796-7816.
24. N. Ramsden, K. Bell, A. Cansfield, J. Taylor, M. Sunose, D. Middlemiss, G. Neubauer, Amino triazoles as PI3K inhibitors, WO 2009/068482 A1, P. C. T. Int., 4 June 2009.
25. A. Pappne Behr, Z. Kapui, P. Aranyi, S. Batori, V. Bartane Bodor, M. Verga, E. mikus, K. Urban-Szabo, J. Vargane Szeredi, T. Szabo, E. Susan, M. Kovacs, Amino-alkyl-amide derivatives as CCR3 receptor ligands, WO 2007/034253 A1, P. C. T. Int., 29 Mar 2007.
26. N.D. Adams, J.L. Burgess, M.G. Darcy, S.D. Knight, K.A. Newlander, L.H. Ridgers, S.J. Schmidt, Quinazoline derivatives as PI3 kinase inhibitors, WO 2008/157191 A2, P. C. T. Int., 24 Dec 2008.